Long-term biochemical response after bisphosphonate therapy in Paget's disease of bone. Proposed intervals for monitoring treatment

Rheumatology

Volumn 43, Issue 7, 2004, Pages 869-874

  Alvarez, L ^a,b   Peris, P ^a   Guanabens N ^a,b   Vidal, S ^a   Quinto Ll ^a   Monegal, A ^a   Pons, F ^a   Ballesta, A M ^a   Munoz Gomez J ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

Bone markers; Treatment

Indexed keywords

ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1; MITHRAMYCIN; TILUDRONIC ACID;

ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; BONE SCINTISCANNING; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DAIRY PRODUCT; DISEASE ACTIVITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; FOOD DRUG INTERACTION; HUMAN; INTESTINE ABSORPTION; LONG TERM CARE; MALE; PAGET BONE DISEASE; PATIENT CODING; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; RELAPSE;

ADULT; AGED; AGED, 80 AND OVER; ALKALINE PHOSPHATASE; BIOLOGICAL MARKERS; COLLAGEN; COLLAGEN TYPE I; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; OSTEITIS DEFORMANS; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 3242885274     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh185     Document Type: Article

References (15)

1. Delmas PD, Meunier PJ. The management of Paget's disease of bone. N Engl J Med 1997;336:558-66.
2. Grauer A, Bone H, McCloskey EV et al. Newer bisphosphonates in the treatment of Paget's disease of bone: where we are and where we want to go. J Bone Miner Res 1999;14(Suppl. 2):74-8.
3. Alvarez L, Guañabens N, Peris P et al. Usefulness of biochemical markers of bone turnover in assessing response to the treatment of Paget's disease. Bone 2001;29:447-52.
4. Selby PL, Davie MWJ, Ralston SH, Stone MD. Guidelines on the management of Paget's disease of bone. Bone 2002;31:366-73.
5. Alvarez L, Peris P, Pons F et al. Relationship between biochemical markers of bone turnover and bone scintigraphic indices in assessment of Paget's disease activity. Arthritis Rheum 1997;40:461-8.
6. Alvarez L, Ricós C, Peris P et al. Components of biological variation of biochemical markers of bone turnover in Paget's disease of bone. Bone 2000;26:571-6.
7. Pons F, Alvarez L, Peris P et al. Quantitative evaluation of bone scintigraphy in the assessment of Paget's disease activity. Nucl Med Commun 1999;20:525-8.
8. Miller PD, Brown J, Siris ES, Hoseyni MS, Axelrod DW, Bekker PJ. A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Am J Med 1999; 106:513-20.
9. Reid IR, Nicholson GC, Weinstein RS et al. Biochemical and radiological improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med 1996; 101:341-8.
10. Roux C, Gennari C, Farrerons J et al. Comparative prospective, double-blind, multicenter study of the efficacy of tiludronate and etidronate in the treatment of Paget's disease of bone. Arthritis Rheum 1995;6:851-8.
11. Papapoulos SE, Frolich M. Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption. J Clin Endocrinol Metab 1996; 81:3993-7.
12. Patel S, Stone MD, Coupland C, Hosking DJ. Determinants of remission of Paget's disease of bone. J Bone Miner Res 1993; 8:1467-73.
13. Patel S, Coupland CAC, Stone MD, Hosking DJ. Comparison of methods of assessing response of Paget's disease to bisphosphonate therapy. Bone 1995;16:193-7.
14. Khan SA, McCloskey EV, Nakatsuka K, Orgee J, Coombes GM, Kanis JA. Duration of response with oral clodronate in Paget's disease of bone. Bone 1996;18:185-90.
15. Roux C, Dougados M. Treatment of patients with Paget's disease of bone. Drugs 1999;58:823-30.